Publication
Exposure-response and dose simulation of belantamab mafodotin in combination with standards of care in patients with relapsed/refractory multiple myeloma.
Sagar Lonial, Paul G Richardson, Geraldine Ferron-Brady, Fernando Carreño, Theodoros Papathanasiou, Yu Liu Ho, Astrid McKeown, Kelly Brock, Sumita Roy-Ghanta, Murad Melhem, Pralay Mukhopadhyay, Hesham A Abdullah, Maria-Victoria Mateos, Meletios A Dimopoulos
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260908-000002
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Belantamab mafodotin is approved globally for relapsed/refractory multiple myeloma (RRMM) based on the phase 3 DREAMM-7 (belantamab mafodotin, bortezomib, dexamethasone [BVd]) and DREAMM-8 (belantamab mafodotin, pomalidomide, dexamethasone) studies. Ocular events in these studies were common,…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMultiple Myelomadictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available